G. Sonpavde, Thomas E. Hutson
Apr 20, 2007
Citations
4
Influential Citations
190
Citations
Quality indicators
Journal
Current Oncology Reports
Abstract
Pazopanib (GW786034) is a second-generation multitargeted tyrosine kinase inhibitor against vascular endothelial growth factor receptor-1,-2, and-3, platelet-derived growth factor receptor-α, platelet-derived growth factor receptor-β, and c-kit. Preclinical evaluation has revealed excellent antiangiogenic and antitumor activity, and synergism was observed in combination with chemotherapeutic drugs. Significant antitumor activity was found in animal models of a variety of tumors, accompanied by desirable pharmacokinetics and oral bioavailability. Phase I clinical trials have revealed manageable toxicities and desirable pharmacokinetics as well as activity in renal cancer and several other tumors. Ongoing trials are further evaluating pazopanib in a variety of malignancies.